Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roberts eliminates backlog of annual reports cited in FDA warning letter.

Executive Summary

ROBERTS ANNUAL REPORT BACKLOG CLEARED FOLLOWING FDA WARNING LETTER that cites the firm for failing to make required reports for approved NDAs. Roberts Pharmaceutical said that it has eliminated the backlog of annual reports that were of concern to FDA. "Your firm has no system for maintaining required records and has failed to maintain required records or make required reports in several instances...regarding approved new drug applications," the Dec. 31 warning letter states.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS031644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel